Hilde Merete Hagen
Fortune : 81 287 $ au 31/08/2026
Fortune : 81 287 $ au 31/08/2026
Hilde Merete Hagen formerly worked at Pronova BioPharma ASA, as Vice President-Quality & Regulatory Affairs, Weifa AS, as Vice President-Quality & Regulatory affairs, and Vistin Pharma ASA, as Vice President-Quality & Regulatory Affairs.
Ms. Hagen received her graduate degree from the University of Oslo and graduate degree from BI Norwegian Business School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VISTIN PHARMA ASA 0,09% | 31/12/2024 | 40 000 ( 0,09% ) | 81 287 $ | 31/08/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: OtherHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Corporate Officer/Principal | - |
Weifa AS
Weifa AS Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Conseiller Juridique Général | - |
| VISTIN PHARMA ASA | Conseiller Juridique Général | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 5 |
|---|---|
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: OtherHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Health Technology |
University of Oslo
University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BI Norwegian Business School
BI Norwegian Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Weifa AS
Weifa AS Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Vistin Pharma ASA
Vistin Pharma ASA Pharmaceuticals: MajorHealth Technology engages in the production of active pharmaceutical ingredients for metformin and opiates | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national